[go: up one dir, main page]

MX2020011453A - Combinaciones para tratar el cancer. - Google Patents

Combinaciones para tratar el cancer.

Info

Publication number
MX2020011453A
MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A
Authority
MX
Mexico
Prior art keywords
sup
treating cancer
combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2020011453A
Other languages
English (en)
Inventor
Scott Boiko
Justin Cidado
Lisa Drew
Theresa Proia
Martin Maryann San
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2020011453A publication Critical patent/MX2020011453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se desvelan métodos de tratamiento del cáncer que comprenden administrar ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia- 5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24. 030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35- tridecaeno-23-carboxílico, una sal farmacéuticamente aceptable del mismo; y acalabrutinib, o una sal farmacéuticamente aceptable del mismo.
MX2020011453A 2018-04-30 2019-04-29 Combinaciones para tratar el cancer. MX2020011453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
MX2020011453A true MX2020011453A (es) 2020-12-07

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011453A MX2020011453A (es) 2018-04-30 2019-04-29 Combinaciones para tratar el cancer.

Country Status (14)

Country Link
US (1) US20210030718A1 (es)
EP (1) EP3787620A1 (es)
JP (1) JP2021522246A (es)
KR (1) KR20210005182A (es)
CN (1) CN112040944A (es)
AU (1) AU2019263026B2 (es)
BR (1) BR112020022020A2 (es)
CA (1) CA3097486A1 (es)
EA (1) EA202092540A1 (es)
MA (1) MA52499A (es)
MX (1) MX2020011453A (es)
SG (1) SG11202010528XA (es)
TW (1) TW202014184A (es)
WO (1) WO2019211721A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4054582T3 (fi) * 2019-11-04 2025-12-04 Astrazeneca Ab Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon
AU2020409006A1 (en) * 2019-12-18 2022-06-30 Zeno Management, Inc. Macrocyclic compounds
AU2022291381B2 (en) 2021-06-11 2025-04-24 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5826931B2 (ja) 2011-07-19 2015-12-02 メルク・シャープ・エンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
US9730938B2 (en) * 2014-08-08 2017-08-15 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
CN109071566B (zh) * 2016-04-22 2021-08-31 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
BR112020022020A2 (pt) 2021-02-02
MA52499A (fr) 2021-04-14
US20210030718A1 (en) 2021-02-04
AU2019263026A1 (en) 2020-12-17
JP2021522246A (ja) 2021-08-30
KR20210005182A (ko) 2021-01-13
EA202092540A1 (ru) 2021-03-17
SG11202010528XA (en) 2020-11-27
CA3097486A1 (en) 2019-11-07
WO2019211721A1 (en) 2019-11-07
CN112040944A (zh) 2020-12-04
TW202014184A (zh) 2020-04-16
EP3787620A1 (en) 2021-03-10
AU2019263026B2 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2020011453A (es) Combinaciones para tratar el cancer.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
HK1259342A1 (zh) 用於治疗癌症的联合疗法
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2021007247A (es) Derivados de rapamicina.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12021552513A1 (en) Pyrrole compounds
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2020055364A3 (en) A pharmaceutical composition comprising eltrombopag olamine
MX2021000935A (es) Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
PH12021552977A1 (en) Methods of treating urinary system cancers
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF